(R)-Carvedilol-d₄  (Synonyms: (R)-BM 14190-d₄)

(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol (HY-B0006C). (R)-Carvedilol ((R)-BM 14190) is the orally active R-isomer of Carvedilol (HY-B0006). (R)-Carvedilol has α-receptor blocking activity but no β-receptor blocking activity. (R)-Carvedilol inhibits spontaneous Ca²⁺ waves. (R)-Carvedilol inhibits stress-induced ventricular tachycardia and delays the development of UV-induced skin tumors and reduces their malignancy^[1][2][3][4].

410.50

C₂₄H₂₂D₄N₂O₄

2747915-92-8

95093-99-5

O[C@H](CNC([2H])([2H])C([2H])([2H])OC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

  [2]. Wu T, et al. Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats. J Appl Toxicol. 2019 Aug;39(8):1233-1244.  [Content Brief]

  [3]. Zhang J, et al. Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure. Biochem J. 2015 Sep 1;470(2):233-42.  [Content Brief]

  [4]. Sardar PK, et al. Oral delivery of the non-β-blocking R-carvedilol enantiomer for skin cancer chemoprevention in SKH-1 mice. AAPS Open. 2025;11:1.  [Content Brief]